← 返回

肿瘤代谢物 2-羟基戊二酸调节抗肿瘤免疫

英文原题:Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity.

查看英文原题

Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity.

PubMed 2024/01/10(内容时间) Heliyon

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

“肿瘤代谢物”2-羟基戊二酸(2-HG)是一种在肿瘤细胞中发现的异常代谢物,对肿瘤进展具有关键影响。近期研究揭示了其对anti-tumor T细胞增殖、活化和分化的影响。此外,2-HG还调控固有免疫成分的功能,包括巨噬细胞、树突状细胞、NK 细胞和补体系统。2-HG水平升高会阻碍α-KG依赖性双加氧酶(α-KGDDs),通过破坏表观遗传调控、基因组完整性、缺氧诱导因子(HIF)信号传导和细胞代谢促进肿瘤发生。2-HG的手性分子结构产生两种对映异构体:D-2-HG和L-2-HG,各自具有不同的来源和生物学功能。抑制D-2-HG并利用L-2-HG潜力的努力已在癌症免疫治疗中显示出疗效。本综述深入探讨2-HG的代谢、生物学功能及其对肿瘤免疫微环境(TIME)的影响,全面探索2-HG与抗肿瘤免疫之间的复杂关系。此外,我们还审视了靶向治疗2-HG的潜在临床应用,重点介绍了近期突破以及现有挑战。

展开英文摘要原文

"Oncometabolite" 2-hydroxyglutarate (2-HG) is an aberrant metabolite found in tumor cells, exerting a pivotal influence on tumor progression. Recent studies have unveiled its impact on the proliferation, activation, and differentiation of anti-tumor T cells.

Moreover, 2-HG regulates the function of innate immune components, including macrophages, dendritic cells, natural killer cells, and the complement system. Elevated levels of 2-HG hinder α-KG-dependent dioxygenases (α-KGDDs), contributing to tumorigenesis by disrupting epigenetic regulation, genome integrity, hypoxia-inducible factors (HIF) signaling, and cellular metabolism.

The chiral molecular structure of 2-HG produces two enantiomers: D-2-HG and L-2-HG, each with distinct origins and biological functions. Efforts to inhibit D-2-HG and leverage the potential of L-2-HG have demonstrated efficacy in cancer immunotherapy. This review delves into the metabolism, biological functions, and impacts on the tumor immune microenvironment (TIME) of 2-HG, providing a comprehensive exploration of the intricate relationship between 2-HG and antitumor immunity.

Additionally, we examine the potential clinical applications of targeted therapy for 2-HG, highlighting recent breakthroughs as well as the existing challenges.

论文信息

作者
Cai M、Zhao J、Ding Q、Wei J
单位
Department of Pharmacy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.China
文献类型
综述
期刊
Heliyon2024 Jan 30
原文标识
PubMed 38293535 · DOI 10.1016/j.heliyon.2024.e24454